SandboxAQ Launches Virtual Screening Solution for GPCR Drug Discovery, Accelerated by NVIDIA BioNeMo

▤ Summary

SandboxAQ launched a virtual screening solution for GPCR drug discovery that uses physics-based modeling and machine learning to predict binding and mechanism of action. The tool helps researchers determine whether a molecule acts as an agonist, antagonist, or inverse agonist before wet-lab testing. SandboxAQ says the workflow can reduce screening costs, shorten medicinal chemistry cycles, and improve confidence in candidate selection. NVIDIA BioNeMo Agent Toolkit accelerates the solution and supports SandboxAQ's broader screening workflows. The company plans to expand the platform across more GPCR classes and harder discovery problems such as orphan receptors and allosteric sites.

▦ Linked Companies

NVIDIA Corporation

$1B+

SandboxAQ

$10M to $25M